Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB25FX1XH
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,085
Award facts
- Contract value 100% obligated
- $20,085.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, with a ceiling value of $20,085.04. The contract calls for the delivery of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials, a long-acting local anesthetic used in surgical and medical settings. The award carries no set-aside designation and is scheduled for ultimate completion by June 24, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and effective through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent contract awards from the DLA covering an extensive portfolio of medications and medical consumables ranging from specialty pharmaceuticals to over-the-counter products and biologics. The company's ability to compete effectively in federal procurement markets reflects its status as a woman-owned small business and its proven capability to reliably distribute pharmaceutical products to military and federal healthcare systems across the nation. This specific delivery order for EXPAREL supports the DLA's mission to provide essential anesthetic medications to Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FX1XH?
SPE2DB25FX1XH was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 2, 2025.
How much is contract SPE2DB25FX1XH worth?
The government has obligated $20,085 on SPE2DB25FX1XH.
Is contract SPE2DB25FX1XH an order under another contract?
Yes. SPE2DB25FX1XH is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB25FX1XH competed?
The extent of competition for SPE2DB25FX1XH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award